Advertisement

Investigational New Drugs

, Volume 13, Issue 4, pp 343–345 | Cite as

Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer

A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)
  • Jean Latreille
  • Yvon Cormier
  • Heidi Martins
  • Glenwood Goss
  • Bryn Fisher
  • Elizabeth A. Eisenhauer
Phase II Studies

Summary

The objective of this multicenter phase II study was to evaluate the activity of docetaxel in previously untreated small cell lung cancer. Fourteen patients were treated at a dose of 75 mg/m2 intravenously every three weeks. Of the 12 patients evaluable for response, one had a partial response for a duration of 12 weeks for a response rate of 8.3%. Toxicity was mild. We conclude that docetaxel has, at the dose given in this study, little activity in previously untreated small cell lung cancer.

Key words

phase II study docetaxel small cell lung cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Verweij J, Clavel M, Chevalier B: Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kind. Annals of Oncology 5:495–505, 1994PubMedGoogle Scholar
  2. 2.
    Smyth JF, Smith IE, Sessa C, Schoffski P, Wanders J, Franklin H, Kaye SB: On behalf of the Early Clinical Trials Group of the EORTC. Activity of Docetaxel (Taxotere) in Small Cell Lung Cancer. Eur J Cancer: Vol 30A, no 8:1058–1060, 1994PubMedGoogle Scholar
  3. 3.
    Ettinger DS, Finkelstein DM, Sarma R, Johnson DH: Phase II study of Taxol in patients with extensive-stage small cell lung cancer: An Eastern Cooperative Oncology Group Study. Proc Am Soc Clin Oncol 12:329, 1993Google Scholar
  4. 4.
    Kirschling RJ, Jung SH, Jett JR: A phase II trial of taxol and GCSF in previously untreated patients with extensivestage small cell lung cancer. Proc Am Soc Clin Oncol 13: 326, 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Jean Latreille
    • 1
  • Yvon Cormier
    • 2
  • Heidi Martins
    • 3
  • Glenwood Goss
    • 4
  • Bryn Fisher
    • 5
  • Elizabeth A. Eisenhauer
    • 5
  1. 1.Hôtel-Dieu de MontréalMontréal
  2. 2.Hôpital LavalSte-Foy
  3. 3.BC Cancer AgencyVictoria ClinicVictoria
  4. 4.General DivisionOttawa Regional Cancer CenterOttawa
  5. 5.National Cancer Institute of Canada Clinical Trials GroupNCIC CTGKingstonCanada

Personalised recommendations